Purpose: Thrombolysis with tissue plasminogen activator (rtPA) is currently used throughout the world in acute ischaemic stroke management. In this review, we will explore the status of our current knowledge about the effects of rtPA on specific rehabilitation domains and highlight some key knowledge gaps. Methods: Narrative review of the larger clinical and postmarketing surveillance studies. Results: To date, most of the previous research into rtPA for acute ischaemic stroke has focused on safety and efficacy using general outcome measures and has ceased following patients 90 days after rtPA administration. This research has provided valuable information about the safety and efficacy of rtPA and has facilitated the introduction of rtPA in...
BACKGROUND: Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic ...
Background and Purpose—A recent placebo-controlled study provided evidence of a sustained benefit at...
BACKGROUND: Stroke is a leading cause of death and disability internationally. One of the three effe...
What is known and Objective: Thrombolysis using intravenous tissue plasminogen activator (tPA) is th...
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed f...
Background: Intravenous tissue plasminogen activator (t-PA) was recognized and approved as the thro...
Abstract Background: Acute ischemic stroke is becoming a prevalent problem in our country debilitati...
Background and Purpose—Recombinant tissue plasminogen activator (rtPA; Actilyse) is not as widely us...
Context According to published articles, thrombosis is the main reason for death all over ...
Introduction: The purpose of this study was to assess safety and efficacy of thrombolysis in the set...
INTRODUCTION: Acute ischemic stroke (AIS) represents a major cause of death and disability all over ...
Thrombolysis is one of the proven potential treatments for the management of acute ischemic stroke. ...
BACKGROUND: A key treatment for acute ischaemic stroke is thrombolysis (rtPA). However, treatment is...
Recombinant tissue plasminogen activator (rtPA) is licensedfor thrombolytic therapy in ischemic stro...
Sherita N Chapman,1 Prachi Mehndiratta,1 Michelle C Johansen,1 Timothy L McMurry,2 Karen C Johnston,...
BACKGROUND: Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic ...
Background and Purpose—A recent placebo-controlled study provided evidence of a sustained benefit at...
BACKGROUND: Stroke is a leading cause of death and disability internationally. One of the three effe...
What is known and Objective: Thrombolysis using intravenous tissue plasminogen activator (tPA) is th...
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed f...
Background: Intravenous tissue plasminogen activator (t-PA) was recognized and approved as the thro...
Abstract Background: Acute ischemic stroke is becoming a prevalent problem in our country debilitati...
Background and Purpose—Recombinant tissue plasminogen activator (rtPA; Actilyse) is not as widely us...
Context According to published articles, thrombosis is the main reason for death all over ...
Introduction: The purpose of this study was to assess safety and efficacy of thrombolysis in the set...
INTRODUCTION: Acute ischemic stroke (AIS) represents a major cause of death and disability all over ...
Thrombolysis is one of the proven potential treatments for the management of acute ischemic stroke. ...
BACKGROUND: A key treatment for acute ischaemic stroke is thrombolysis (rtPA). However, treatment is...
Recombinant tissue plasminogen activator (rtPA) is licensedfor thrombolytic therapy in ischemic stro...
Sherita N Chapman,1 Prachi Mehndiratta,1 Michelle C Johansen,1 Timothy L McMurry,2 Karen C Johnston,...
BACKGROUND: Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic ...
Background and Purpose—A recent placebo-controlled study provided evidence of a sustained benefit at...
BACKGROUND: Stroke is a leading cause of death and disability internationally. One of the three effe...